Results 231 to 240 of about 482,159 (313)
Effect of GLP-1 receptor agonists on upper gastrointestinal endoscopy outcomes: a systematic review and meta-analysis. [PDF]
Malandris K +10 more
europepmc +1 more source
Abstract Objective Different therapies may affect the growth and development of children and adolescents with inflammatory bowel disease (IBD) supporting specific therapy algorithms for paediatric Crohn's disease (CD) and ulcerative colitis (UC). Methods Growth and development data from the German–Austrian CEDATA‐GPGE registry entered between 2004 and ...
Ilse Broekaert +4 more
wiley +1 more source
Remimazolam versus midazolam for sedation in diagnostic upper gastrointestinal endoscopy: study protocol for a randomized controlled trial. [PDF]
Ahn DW +7 more
europepmc +1 more source
Abstract Objectives Anaemia impairs daily activities and quality of life in patients with paediatric‐onset inflammatory bowel disease (PIBD). This study aimed to investigate the prevalence of anaemia at PIBD‐diagnosis and the following 5 years. Furthermore, anaemia subtypes and the association between anaemia and disease activity were assessed over ...
Julie Rahbek Norup +3 more
wiley +1 more source
Quality metrics reflecting patient experience of gastrointestinal endoscopy in inflammatory bowel disease: results of national endoscopy dataset analysis. [PDF]
Jones F +13 more
europepmc +1 more source
Abstract Objective Nutritional therapy is a cornerstone for the induction of remission in pediatric Crohn's disease (CD); however, the optimal dietary strategy remains uncertain. This study aimed to compare the short‐ and long‐term therapeutic outcomes of exclusive enteral nutrition (EEN) and the Crohn's disease exclusion diet (CDED) in a large cohort ...
Danielle Pevzner +7 more
wiley +1 more source
The impact of frailty and sarcopenia index on postoperative nausea and vomiting in elderly patients undergoing sedation-assisted gastrointestinal endoscopy. [PDF]
Sun D +5 more
europepmc +1 more source
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan +2 more
wiley +1 more source

